CTT Pharma CEO buys 3,500 shares at $0.049

CTT PHARMACEUTICAL HOLDINGS, INC.

Rhea-AI Filing Summary

CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that its CEO purchased shares of the company’s common stock. On 2026-08-31, the reporting person bought 3,500 shares of CTTH in a purchase described as an open market or private transaction at $0.049 per share, bringing the reported direct holdings to 9,384,256 shares.

Insider Trade Summary

Net Buyer: 3,500 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 3,500 shs ($171.50)

Type	Security	Shares	Price	Value
Purchase	CTTH	3,500	$0.049	$171.50

Holdings After Transaction: CTTH — 9,384,256 shares (Direct)

Key Figures

Shares purchased: 3,500 shares Purchase price per share: $0.049 per share Shares owned after transaction: 9,384,256 shares

3 metrics

Shares purchased 3,500 shares Non-derivative purchase on 2026-08-31

Purchase price per share $0.049 per share Open market or private transaction on 2026-08-31

Shares owned after transaction 9,384,256 shares Direct ownership reported following the purchase

Key Terms

Form 4, open market or private transaction, direct ownership

3 terms

Form 4 regulatory

"The Form 4 for CTTH reports a buy transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction financial

"purchase in an open market or private transaction at $0.049"

direct ownership financial

"shares held directly following the purchase"

FAQ

What insider transaction did CTTH report in this Form 4?

CTT PHARMACEUTICAL HOLDINGS, INC. reported a purchase of 3,500 CTTH shares on 2026-08-31 at $0.049 per share in an open market or private transaction.

How many CTTH shares does the reporting person hold after this transaction?

Following the reported transaction, the filing shows the reporting person with 9,384,256 CTTH shares held directly.

Was the CTTH insider transaction a buy or a sell?

The Form 4 for CTTH reports a buy transaction: a purchase of 3,500 shares coded as a purchase in an open market or private transaction.

What was the price per share in the reported CTTH insider purchase?

The reported insider purchase of CTTH shares was executed at a price of $0.049 per share for 3,500 shares.

Is the CTTH insider transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is unchecked, so this reported CTTH transaction is not identified as being effected under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 02:13 PM Accepted by SEC EDGAR 08/31/2026 - 02:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	08/31/2026		P		3,500	A	$0.049	9,384,256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)